Evaluation of commercial Guardant360 ctDNA test in metastatic prostate cancer

ABSTRACT: Circulating tumor DNA (ctDNA) sequencing provides a minimally-invasive method for tumor molecular stratification. We compared the commercial Guardant360 ctDNA test to an academic sequencing approach for profiling of metastatic prostate cancer. Plasma cell-free DNA (cfDNA) from 24 patients was sequenced with a validated, prostate cancer specific targeted research panel, and sent for simultaneous Guardant360 analysis.

PROVIDER: EGAS00001003352 | EGA |

REPOSITORIES: EGA